News & Media

282025-03

Mabgeek Biotech has officially moved into WORLO COMPUTING-CHANGSHA INTELLIGENCE VALLEY

092026-06

Mo Xian., et al. 2026, Clinical &Experimental Allergy

Clin Experimental Allergy - 2026 - Xian - Phase Ib II Study of Preliminary Efficacy Safety and Phar
302026-04

The patent for the sequence and application of MG-K10, a monoclonal antibody developed by Mabgeek Biotech, has been maintained as valid.

After the patent (ZL202010309238.8) independently developed and held by Mabgeek Biotech was subject
242026-04

A single dose provides long-lasting coverage throughout the entire seasonal allergy period - MG-K10, a new drug of Class 1 from Mabgeek Biotech, has received acceptance for its NDA application for the indication of seasonal allergic rhinitis.

Kemikebaizhantong is an innovative long-acting humanized monoclonal antibody against IL-4Rα independ

Technological innovation

Efficient integration; Establish an efficient antigen-antibody expression and purification platform.

All team members come from well-known domestic pharmaceutical companies, and the team has over three years of cooperation experience.

The company has a 500-square-meter laboratory and four cell culture rooms.

Independent R&D and clinical development of innovative antibodies have resulted in the first domestic market launch and the first global submission.

About Us

About
R&D
- Areas
- Pipeline
- Platforms
Publications
- MG-K10
- MG-ZG122
Careers
- Culture
- Join Us

Contact Us

ADD:No.5, Building 34, Lane 122, Chunxiao Road, Zhangjiang Town, Pudong New Area, Shanghai
TEL: +86-21-51371305
EMAlL:info@mabgeek.com

All Rights Reserved by HUNAN MABGEEK BIOTECH CO., LTD © 2018-2024 mabge.com

湘ICP备2024096314号公安部备案：31011502015815